ArticleTuberkuloz ve toraks2024
The effectiveness of telemedicine methods in the follow-up of asthma in the COVID-19 pandemic process.
Article in Tuberkuloz ve toraks, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Remote visits for severe asthma patients after the COVID-19 pandemic: how to address the challenge?Revista clinica espanola · 2023Article
- [Remote visits for severe asthma patients after the COVID-19 pandemic: How to address the challenge?]Revista clinica espanola · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Telemedicine is a health service that provides diagnosis, treatment evaluation, preventive medicine by using information and communication technologies between distant locations and aims to improve the health of the individuals and society. Social restrictions were applied during the pandemic process caused by coronavirus disease-2019 due to the virus called severe acute respiratory syndrome coronavirus-2 which emerged in late 2019. Through remote communication and information technologies in the followup of asthma patients, there is a need for studies on the effectiveness of using telemedicine methods was seen. Materials and Methods: Our study included 328 patients aged 18 to 65 who were diagnosed with asthma and followed up by our team. The clinical evaluations and scale results of these patients were conducted at least three times by a single physician using telemedicine applications. In our study, the control group consisted of routine control results from asthma patients, who were reachable via hospital records before the pandemic, covering a one-year period. This file review includes data from October 1, 2019, to October 1, 2020. Result: Three hundred and twenty-eight patients with asthma were included in the study. When the current data of the participants were compared with face-to-face data before follow-up with telemedicine, no statistically significant difference was found (p> 0.05). Although there was a slight decrease in asthma control test scores during the follow-up, it was not statistically significant (p> 0.05). A statistically significant difference was found in severe persistent asthma as a result of the comparison of the asthma control test results of the participants in follow-up according to disease severity (p<0.05). In this study, when the effect of the presence of comorbidity on asthma control test results in follow-up was examined, statistically significant results were obtained (p<0.05). Conclusions: It is predicted that telemedicine will have an important place in disease control since asthma is a disease that requires close monitoring. Disease follow-up with telemedicine was predicted to be a good alternative to traditional face-to-face follow-ups in selected patient groups. This study also supported the effectiveness of telemedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.